Documents produced on discovery and recently unsealed during litigation suggested how AstraZeneca handled clinical research data in the marketing of its atypical anti-psychotic drug Seroquel (quetiapine).
As reported by Bloomberg ,
AstraZeneca Plc 'buried' unfavorable studies on its antipsychotic drug Seroquel, according to an internal e-mail unsealed as part of litigation over the medicine.
The drugmaker failed to publicize results of at least three clinical trials of Seroquel and engaged in 'cherry picking' of...
Post new comment